Rescue therapy with Sofosbuvir /Velpatasvir/ Voxilaprevir in a patient infected with Hepatitis C virus multidrug resistant variant—a much needed option for DAA-treatment failures in Pakistan? A case-report
Year: 2024
Type: article
Study design: Case Report
Abstract: Primary non-response to the currently available direct acting anti-viral (DAAs) in chronic hepatitis C virus (HCV) is rare and expected in approximately only 3-4% of the patients. Among the plausible explanations, HCV resistant variant may be one of the causes among the several other viral and host factors implicated in cases who do not achieve cure. Ever since the approval of licensed DAAs in 2014, focus has been mainly on high cure rates. Hence, significantly less attention has been given to the few difficult to treat cases. We present, herein, the case of a 50-year old male who had previously failed to respond to the currently available first and second-line DAA treatment and was then approved for a special treatment access programme. According to our knowledge this is the first case-report from Pakistan in favour of the physician's directive for special treatment access for HCV DAA-experienced patients.
DOI: 10.47391/jpma.11595
Authors: Ambreen Arif, Huma Qureshi
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $650
OpenAlex ID: W4402731555